Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Earnings Data
Report Date
Sep 09, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.54Last Year’s EPS
-1.91Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -5.93%
|Next Earnings Date:Sep 09, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights Ascendis Pharma's strong launch and revenue growth for YORVIPATH, alongside significant advances in their product pipeline. However, this success is tempered by increased operating expenses and ongoing challenges in securing insurance reimbursements. Overall, the sentiment is balanced with significant achievements and operational challenges.Company Guidance
During the Ascendis Pharma First Quarter 2025 Earnings Conference Call, the company provided guidance on several key metrics and strategic initiatives. For the first quarter ending March 31, 2025, YORVIPATH generated €45 million in revenue, up from €40 million in the previous quarter, with more than 1,750 patients in the U.S. receiving prescriptions from over 1,000 unique prescribers. SKYTROFA, another key product, achieved €51 million in revenue, capturing around 7% of the total U.S. growth hormone market and 43% of the long-acting segment. Ascendis anticipates YORVIPATH will significantly impact its 2025 financial profile, projecting revenue growth as market access expands in Europe. The company is also advancing its TransCon CNP pipeline, with an NDA submission to the FDA in March and an MAA filing expected with EMEA in Q3 2025. Ascendis aims to continue building on its U.S. and European market successes, with strategic plans for clinical trial expansions and regulatory filings to support its growth trajectory.Successful Launch of YORVIPATH
YORVIPATH, the first and only FDA approved treatment for hypoparathyroidism in adults, was prescribed by over 1,000 unique prescribers for more than 1,750 patients in the U.S. in its first quarter since launch.
Strong Revenue Growth
Total global YORVIPATH revenue grew to €45 million in Q1 2025 from €40 million in Q4 2024. SKYTROFA revenues reached €51 million, capturing 7% of the total U.S. growth hormone market.
Advancement of Pipeline Products
The company submitted an NDA to the FDA for TransCon CNP in March and is planning to file an MAA with EMEA in Q3 2025. TransCon CNP has shown promise in treating achondroplasia.
Positive Financial Position
As of March 31, 2025, Ascendis Pharma had cash and cash equivalents totaling €518 million, supporting continued growth and development.
---
ASND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ASND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $167.47 | $172.06 | +2.74% |
Feb 12, 2025 | $126.14 | $142.49 | +12.96% |
Nov 14, 2024 | $124.28 | $126.51 | +1.79% |
Sep 03, 2024 | $134.68 | $119.50 | -11.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ascendis Pharma (ASND) report earnings?
Ascendis Pharma (ASND) is schdueled to report earning on Sep 09, 2025, TBA Not Confirmed.
What is Ascendis Pharma (ASND) earnings time?
Ascendis Pharma (ASND) earnings time is at Sep 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASND EPS forecast?
ASND EPS forecast for the fiscal quarter 2025 (Q2) is -1.54.
---